RATIONALIZATION OF COST ACCOUNTING WITH THE DARO 8205 SMALL COMPUTER.MATSCHENZ R; THALER J.1975; NEUE TECH. BUERO; DTSCH.; DA. 1975; VOL. 19; NO 5; PP. 138-141Article

Data-acquisition modeling and simulationTHALER, J. J.Computer physics communications. 1989, Vol 57, Num 1-3, pp 309-312, issn 0010-4655, 4 p.Conference Paper

Expression of LFA-1 identifies different prognostic subgroups in patients with advanced follicle center lymphoma (FCL)BECHTER, O. E; EISTERER, W; DIRNHOFER, S et al.Leukemia research. 1999, Vol 23, Num 5, pp 483-488, issn 0145-2126Article

Abundance of phytoseiid mites on Vitis species : effects of leaf hairs, domatia, prey abundance and plant phylogenyKARBAN, R; ENGLISH-LOEB, G; WALKER, M. A et al.Experimental & applied acarology. 1995, Vol 19, Num 4, pp 189-197, issn 0168-8162Article

SUR L'EXISTENCE EN EUROPE DE QUATRE GROUPES DE SOURIS (GENRE MUS L.) DU RANG ESPECE ET SEMI-ESPECE, DEMONTREE PAR LA GENETIQUE BIOCHIMIQUEBONHOMME F; BRITTON DAVIDIAN J; THALER J et al.1978; C.R. ACAD. SCI., D; FRA; DA. 1978; VOL. 287; NO 6; PP. 631-633; ABS. ENG; BIBL. 7 REF.Article

Infusion reactions to the chimeric EGFR inhibitor cetuximab—change to the fully human anti-EGFR monoclonal antibody panitumumab is safeRESCH, G; SCHABERL-MOSER, R; KIER, P et al.Annals of oncology. 2011, Vol 22, Num 2, pp 486-487, issn 0923-7534, 2 p.Article

Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosisHILBE, W; DIRNHOFER, S; OBERWASSERLECHNER, F et al.Journal of clinical pathology. 2003, Vol 56, Num 10, pp 736-741, issn 0021-9746, 6 p.Article

Pentostatin in T-cell malignancies : a phase II trial of the EORTCHO, A. D; SUCIU, S; ZITTOUN, R et al.Annals of oncology. 1999, Vol 10, Num 12, pp 1493-1498, issn 0923-7534Article

Interferon-alpha-2c and LD ara-C for the treatment of patients with CML : Results of the Austrian multi-center phase II studyTHALER, J; HILBE, W; ABBREDERIS, K et al.Leukemia research. 1997, Vol 21, Num 1, pp 75-80, issn 0145-2126Article

Modulation of transferrin receptor expression by dexrazoxane (ICRF-187) via activation of iron regulatory proteinWEISS, G; KASTNER, S; BROCK, J et al.Biochemical pharmacology. 1997, Vol 53, Num 10, pp 1419-1424, issn 0006-2952Article

An aggressive subtype of B-CLL is characterized by strong CD44 expression and lack of CD11cEISTERER, W; HILBE, W; STAUDER, R et al.British journal of haematology. 1996, Vol 93, Num 3, pp 661-669, issn 0007-1048Article

Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission : an analysis of the EORTC-GIMEMA AML 8A TrialKEATING, S; SUCIU, S; BIZZI, B et al.Bone marrow transplantation (Basingstoke). 1996, Vol 17, Num 6, pp 993-1002, issn 0268-3369, 9 p.Article

Decreased potency of MDR-modulators under serum conditions determined by a functional assayLUDESCHER, C; EISTERER, W; HILBE, W et al.British journal of haematology. 1995, Vol 91, Num 3, pp 652-657, issn 0007-1048Article

Treatment of relapsed and refractory acute myelogenous leukamia with aclacinomycin a (ACA) and etoposide (VP-16)HILBE, W; THALER, J; EISTERER, W et al.Leukemia research. 1994, Vol 18, Num 9, pp 655-658, issn 0145-2126Article

Pentostatin in prolymphocytic leukemia : phase II trial of the European Organization for Research and Treatment of Cancer leukemia cooperative study groupDÖHNER, H; HO, A. D; SOLBU, G et al.Journal of the National Cancer Institute. 1993, Vol 85, Num 8, pp 658-662, issn 0027-8874Article

Comparison of clinical efficacy and toxicity of conventional and optimum biological response modifying doses of interferon alpha-2C in the treatment of hairy cell leukemia: a retrospective analysis of 39 patientsGASTL, G; WERTER, M; COSER, P et al.Leukemia. 1989, Vol 3, Num 6, pp 453-460, issn 0887-6924Article

Treatment of patients with advanced chronic myelogenous leukemia with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01): a pilot studyKÜHR, T; EISTERER, W; THALER, J et al.Leukemia research. 2000, Vol 24, Num 7, pp 583-587, issn 0145-2126Article

T-cell subsets in schizophrenia : a comparison between drug-naive first episode patients and chronic schizophrenic patientsSPERNER-UNTERWEGER, B; WHITWORTH, A; KEMMLER, G et al.Schizophrenia research. 1999, Vol 38, Num 1, pp 61-70, issn 0920-9964Article

Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia : results of a phase-II trialSCHNELLER, F; SCHULER, M; SCHUMACHER, K et al.Annals of hematology (Print). 1998, Vol 77, Num 5, pp 225-229, issn 0939-5555Article

Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemiaBECHTER, O. E; EISTERER, W; PALL, G et al.Cancer research (Baltimore). 1998, Vol 58, Num 21, pp 4918-4922, issn 0008-5472Article

Different CD44 splicing patterns define prognostic subgroups in multiple myelomaSTAUDER, R; VAN DRIEL, M; SCHWÄRZLER, C et al.Blood. 1996, Vol 88, Num 8, pp 3101-3108, issn 0006-4971Article

Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia : A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative GroupZITTOUN, R; SUCIU, S; PETTI, M. C et al.Journal of clinical oncology. 1996, Vol 14, Num 7, pp 2150-2159, issn 0732-183XArticle

Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemiaLUDESCHER, C; EISTERER, W; HILBE, W et al.Leukemia. 1995, Vol 9, Num 2, pp 350-356, issn 0887-6924Article

Bone marrow lymphocyte subsets in myelodysplastic syndromesHILBE, W; EISTERER, W; SCHMID, C et al.Journal of clinical pathology. 1994, Vol 47, Num 6, pp 505-507, issn 0021-9746Article

Successful second transplant from an HLA-identical unrelated donor after graft rejection in a patient with chronic myelogenous leukemiaNACHBAUR, D; SCHWAIGHOFER, H; PETERSEN, F et al.Transplantation. 1994, Vol 57, Num 3, pp 479-480, issn 0041-1337Article